We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Hamburg: I-SPY 2 and New Office to Boost New Regulatory Science
Hamburg: I-SPY 2 and New Office to Boost New Regulatory Science
October 13, 2010
The I-SPY 2 trial, a model that uses biomarkers to individually target drugs in development to the biology of a woman’s tumors, is one of the examples FDA Commissioner Margaret Hamburg cited as she explained how the agency will capitalize on new regulatory science.